Drug Trial Radar · NCT01163253
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Jun 26, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2,867
Actual
Start
Sep 2010
Primary completion
Jun 2016
Study completion Jun 2016
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jul 15, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis. This is an open label extension study available to patients who participated in one of the qualifying studies with CP-690,550 providing entry criteria is met.
Conditions
- Psoriasis
Interventions
CP-690,550Drug
5 mg oral BID
CP-690,550Drug
10 mg oral BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
- Number of Adverse Events (AEs) by SeverityTime frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
- Number of Participants With Laboratory AbnormalitiesTime frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
- Change From Baseline in Hemoglobin Level at Month 1Time frame: Baseline, Month 1
- Change From Baseline in Hemoglobin Level at Month 3Time frame: Baseline, Month 3
- Change From Baseline in Hemoglobin Level at Month 6Time frame: Baseline, Month 6
- Change From Baseline in Hemoglobin Level at Month 12Time frame: Baseline, Month 12
- Change From Baseline in Hemoglobin Level at Month 24Time frame: Baseline, Month 24
- Change From Baseline in Hemoglobin Level at Month 36Time frame: Baseline, Month 36
- Change From Baseline in Hemoglobin Level at Month 48Time frame: Baseline, Month 48
- Change From Baseline in Lymphocyte and Neutrophil Count at Month 1Time frame: Baseline, Month 1
- Change From Baseline in Lymphocyte and Neutrophil Count at Month 3Time frame: Baseline, Month 3
- Change From Baseline in Lymphocyte and Neutrophil Count at Month 6Time frame: Baseline, Month 6
- Change From Baseline in Lymphocyte and Neutrophil Count at Month 12Time frame: Baseline, Month 12
- Change From Baseline in Lymphocyte and Neutrophil Count at Month 24Time frame: Baseline, Month 24
- Change From Baseline in Lymphocyte and Neutrophil Count at Month 36Time frame: Baseline, Month 36
- Change From Baseline in Lymphocyte and Neutrophil Count at Month 48Time frame: Baseline, Month 48
- Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 1Time frame: Baseline, Month 1
- Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 3Time frame: Baseline, Month 3
- Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 6Time frame: Baseline, Month 6
- Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 12Time frame: Baseline, Month 12
- Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 24Time frame: Baseline, Month 24
- Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 36Time frame: Baseline, Month 36
- Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 48Time frame: Baseline, Month 48
- Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 1Time frame: Baseline, Month 1
- Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 3Time frame: Baseline, Month 3
- Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 6Time frame: Baseline, Month 6
- Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 12Time frame: Baseline, Month 12
- Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 24Time frame: Baseline, Month 24
- Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 36Time frame: Baseline, Month 36
- Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 48Time frame: Baseline, Month 48
- Number of Participants With Clinically Significant Change From Baseline in Physical ExaminationTime frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
- Number of Participants With Vital Sign AbnormalitiesTime frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
- Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 1Time frame: Baseline, Month 1
- Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 3Time frame: Baseline, Month 3
- Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 6Time frame: Baseline, Month 6
- Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 12Time frame: Baseline, Month 12
- Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 24Time frame: Baseline, Month 24
- Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 36Time frame: Baseline, Month 36
- Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 48Time frame: Baseline, Month 48
- Change From Baseline in Heart Rate at Month 1Time frame: Baseline, Month 1
- Change From Baseline in Heart Rate at Month 3Time frame: Baseline, Month 3
- Change From Baseline in Heart Rate at Month 6Time frame: Baseline, Month 6
- Change From Baseline in Heart Rate at Month 12Time frame: Baseline, Month 12
- Change From Baseline in Heart Rate at Month 24Time frame: Baseline, Month 24
- Change From Baseline in Heart Rate at Month 36Time frame: Baseline, Month 36
- Change From Baseline in Heart Rate at Month 48Time frame: Baseline, Month 48
- Number of Participants With Electrocardiogram (ECG) AbnormalitiesTime frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
- Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 6Time frame: Baseline, Month 6
- Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 12Time frame: Baseline, Month 12
- Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 24Time frame: Baseline, Month 24
- Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 36Time frame: Baseline, Month 36
- Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 48Time frame: Baseline, Month 48
- Number of Participants With Adjudicated Cardiovascular EventsTime frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
- Number of Participants With Malignancy EventsTime frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
Locations
323 sites in 36 countries. Site status is shown where the registry gives one.
Radiant Research, Inc.
Birmingham, Alabama
UAB Dermatology
Birmingham, Alabama
Horizon Research Group, Inc.
Mobile, Alabama
Radiant Research, Inc.
Tucson, Arizona
Burke Pharmaceutical Research
Hot Springs, Arkansas
Bakersfield Dermatology and Skin Cancer Medical Group
Bakersfield, California
Associates In Research, Inc.
Fresno, California
University of California Irvine
Irvine, California
Dermatology Research Associates
Los Angeles, California
Dermatology Specialists, Inc.
Oceanside, California
MedDerm Associates
San Diego, California
UCSD Dermatology
San Diego, California
University of California San Diego
San Diego, California
University of California San Francisco
San Francisco, California
Clinical Science Institute
Santa Monica, California
Healthcare Partners Medical Group
Torrance, California
Cherry Creek Research, Inc.
Denver, Colorado
The Savin Center, P.C.
New Haven, Connecticut
New England Research Associates, LLC
Trumbull, Connecticut
Florida Academic Dermatology Center
Coral Gables, Florida
North Florida Dermatology Associates, PA
Jacksonville, Florida
International Dermatology Research, Inc.
Miami, Florida
Renstar Medical Research
Ocala, Florida
Park Avenue Dermatology, PA
Orange Park, Florida
Leavitt Medical Associates of Florida dba Ameriderm Research
Ormond Beach, Florida
Miami Research Associates, Inc.
South Miami, Florida
Olympian Clinical Research
Tampa, Florida
Atlanta Dermatology, Vein & Research Center, P.C.
Alpharetta, Georgia
Advanced Medical Research, Inc.
Atlanta, Georgia
MedaPhase Inc.
Newnan, Georgia
Altman Dermatology Associates
Arlington Heights, Illinois
Schaumburg Dermatology
Schaumburg, Illinois
NorthShore University Health System - Division of Dermatology
Skokie, Illinois
Springfield Clinic
Springfield, Illinois
Dundee Dermatology
West Dundee, Illinois
Deaconess Clinic Downtown Research Institute
Evansville, Indiana
Hudson Dermatology
Evansville, Indiana
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
DermResearch, PLLC
Louisville, Kentucky
Tufts Medical Center
Boston, Massachusetts
Showing 40 of 323 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.